1.2 Neurotransmitters and Synaptic Transmission

1.2 Neurotransmitters and Synaptic Transmission

Synaptic transmission is the chemical foundation of neurocommunication and psychopharmacology. Modern psychiatric medications exert therapeutic efficacy—and adverse effect profiles—by modulating neurotransmitter synthesis, vesicular storage, axonal release, synaptic reuptake, enzymatic degradation, and postsynaptic/presynaptic receptor binding. The PMHNP must master the physiological pathways and receptor dynamics of monoamines, amino acids, and acetylcholine to safely prescribe and manage psychotropic regimens.

---

Monoaminergic Systems

1. Dopamine (DA)

Dopamine is synthesized from the amino acid L-tyrosine via the intermediate L-DOPA, catalyzed by tyrosine hydroxylase (the rate-limiting enzyme). Dopamine receptors belong to the G-protein coupled receptor (GPCR) superfamily and are divided into two main families:

• D1-like Family (D1, D5): Coupled to $G_{\alpha s}$, stimulating adenylyl cyclase and increasing intracellular cyclic AMP (cAMP).
• D2-like Family (D2, D3, D4): Coupled to $G_{\alpha i}$, inhibiting adenylyl cyclase, decreasing cAMP, and opening potassium channels. The D2 receptor is the principal target for all FDA-approved antipsychotic medications.

+-----------------------------------------------------------------------------------+
|                        FOUR MAJOR DOPAMINERGIC PATHWAYS                           |
+--------------------+-------------------------+--------------------+---------------+
| Pathway            | Anatomical Origin/Target| Primary Function   | Clinical Impact|
+--------------------+-------------------------+--------------------+---------------+
| Mesolimbic         | VTA -> Nucleus Accumbens| Reward, motivation,| Hyper: Positive|
|                    |                         | pleasure, psychosis| symptoms. D2  |
|                    |                         |                    | block = anti- |
|                    |                         |                    | psychotic     |
+--------------------+-------------------------+--------------------+---------------+
| Mesocortical       | VTA -> DLPFC & vmPFC    | Cognition, affect, | Hypo: Negative|
|                    |                         | executive function | symptoms. D2  |
|                    |                         |                    | block worsens |
|                    |                         |                    | cognition     |
+--------------------+-------------------------+--------------------+---------------+
| Nigrostriatal      | Substantia Nigra ->     | Voluntary movement | D2 block =    |
|                    | Striatum                | control            | EPS, TD,      |
|                    |                         |                    | Parkinsonism  |
+--------------------+-------------------------+--------------------+---------------+
| Tuberoinfundibular | Hypothalamus ->         | Inhibits prolactin | D2 block =    |
|                    | Anterior Pituitary      | secretion          | Hyperprolactin|
|                    |                         |                    | emia          |
+--------------------+-------------------------+--------------------+---------------+

The Four Primary Dopaminergic Pathways

1. Mesolimbic Pathway: Projects from the Ventral Tegmental Area (VTA) to the Nucleus Accumbens (limbic ventral striatum). Hyperactivity of dopaminergic transmission in this pathway generates positive psychotic symptoms (delusions, hallucinations, thought disorganization). D2 receptor antagonism in this pathway reduces positive symptoms.
2. Mesocortical Pathway: Projects from the VTA to the Dorsolateral PFC and Ventromedial PFC. Dopaminergic hypofunction in this pathway underlies negative symptoms (avolition, alogia, affective flattening) and cognitive deficits in Schizophrenia. Conventional antipsychotic D2 blockade can potentially worsen negative and cognitive symptoms in this pathway.
3. Nigrostriatal Pathway: Projects from the Substantia Nigra to the Striatum (Caudate/Putamen), forming a vital part of the basal ganglia motor loop. Unmediated D2 antagonism in this pathway (>80% receptor occupancy) produces Extrapyramidal Symptoms (EPS) including acute dystonia, akathisia, parkinsonism, and long-term Tardive Dyskinesia (TD) via dopamine receptor upregulation and supersensitivity.
4. Tuberoinfundibular Pathway: Projects from the arcuate nucleus of the hypothalamus to the anterior pituitary gland. Tonic dopamine release onto pituitary lactotroph D2 receptors inhibits prolactin secretion. D2 antagonism causes Hyperprolactinemia, leading to galactorrhea, gynecomastia, amenorrhea, sexual dysfunction, and long-term osteopenia/osteoporosis.

---

2. Serotonin (5-Hydroxytryptamine / 5-HT)

Serotonin is synthesized from the essential amino acid L-tryptophan via tryptophan hydroxylase (rate-limiting enzyme) to 5-HTP, and subsequently decarboxylated to 5-HT. Neuronal cell bodies reside in the midline Raphe Nuclei of the brainstem.

Serotonin Receptor Subtypes in Psychopharmacology

With the exception of 5-HT3 (which is an ionotropic ligand-gated ion channel), all 5-HT receptors are GPCRs:

• 5-HT1A Receptors: Located presynaptically as somatodendritic autoreceptors (inhibiting 5-HT firing) and postsynaptically in cortical/limbic regions. Postsynaptic 5-HT1A partial agonism (e.g., Buspirone, Aripiprazole, Vilazodone) exerts potent anxiolytic and antidepressant effects.
• 5-HT2A Receptors: Postsynaptic GPCRs coupled to $G_{\alpha q}$ (activating phospholipase C). Postsynaptic 5-HT2A activation mediates hallucinogenic activity (classic psychedelics like LSD/psilocybin). Crucially, 5-HT2A receptor antagonism is the defining pharmacological feature of Second-Generation (Atypical) Antipsychotics (e.g., Risperidone, Olanzapine). By blocking 5-HT2A receptors on cortical glutamate neurons, atypical antipsychotics disinhibit dopamine release in the nigrostriatal pathway, markedly reducing EPS risk.
• 5-HT2C Receptors: Modulates satiety, mood, and mesolimbic dopamine release. 5-HT2C antagonism (e.g., Olanzapine, Clozapine) is strongly linked to hyperphagia, severe metabolic syndrome, and weight gain, but also contributes to prefrontal dopamine release.
• 5-HT3 Receptors: Ionotropic Na+/K+ channels located in the Area Postrema (chemoreceptor trigger zone) and gastrointestinal tract. 5-HT3 antagonism (e.g., Ondansetron, Vortioxetine) treats chemotherapy-induced nausea and enhances cognitive function by disinhibiting acetylcholine and norepinephrine release.

---

3. Norepinephrine (NE)

Norepinephrine is synthesized from dopamine by the enzyme dopamine $\beta$-hydroxylase within noradrenergic neurons originating primarily in the Locus Coeruleus. NE acts on $\alpha_1$, $\alpha_2$, and $\beta$-adrenergic receptors:

• $\alpha_1$-Adrenergic Receptors ($G_{\alpha q}$): Postsynaptic excitation. $\alpha_1$ blockade (e.g., Prazosin) suppresses central noradrenergic hyperarousal, making it an effective evidence-based treatment for PTSD-related nightmares. $\alpha_1$ blockade by antipsychotics also causes orthostatic hypotension and sedation.
• $\alpha_2$-Adrenergic Receptors ($G_{\alpha i}$): Presynaptic autoreceptors that exert negative feedback control, inhibiting further NE and insulin release. Presynaptic $\alpha_2$ agonists (Clonidine, Guanfacine) reduce sympathetic outflow, serving as key non-stimulant treatments for ADHD and autonomic hyperarousal in PTSD and substance withdrawal. Conversely, $\alpha_2$ antagonism (Mirtazapine) disinhibits NE and 5-HT release ('central presynaptic $\alpha_2$ antagonist').

+-----------------------------------------------------------------------------------+
|                     RECEPTOR BINDING AND CLINICAL CORRELATES                      |
+-------------------+------------------+--------------------------------------------+
| Receptor Target   | Signaling Mechanism| Clinical / Psychopharmacological Impact   |
+-------------------+------------------+--------------------------------------------+
| D2 Antagonism     | Gi / Decreased   | Anti-psychotic effect (Mesolimbic);        |
|                   | cAMP             | EPS (Nigrostriatal); Prolactin (Tuberoinf.)|
+-------------------+------------------+--------------------------------------------+
| 5-HT2A Antagonism | Gq / Decreased   | Reduces EPS risk; enhances prefrontal DA;  |
|                   | Inositol Tri-P   | pro-cognitive and atypical profile         |
+-------------------+------------------+--------------------------------------------+
| 5-HT2C Antagonism | Gq / Decreased   | Increased appetite, weight gain, metabolic |
|                   | Phospholipase C  | risk (Olanzapine, Clozapine)               |
+-------------------+------------------+--------------------------------------------+
| alpha-1 Antagonism| Gq / Vascular    | Orthostatic hypotension, reflex tachycardia|
|                   | smooth muscle    | Nightmare suppression in PTSD (Prazosin)   |
+-------------------+------------------+--------------------------------------------+
| H1 Antagonism     | Gq / Histaminergic| Sedation, somnolence, weight gain          |
+-------------------+------------------+--------------------------------------------+
| M1 Antagonism     | Gq / Cholinergic | Dry mouth, blurred vision, urinary retention|
|                   |                  | constipation, cognitive impairment/delirium|
+-------------------+------------------+--------------------------------------------+

---

Amino Acid Neurotransmitter Systems

1. Glutamate (Major Excitatory Neurotransmitter)

Glutamate is the primary excitatory neurotransmitter in the mammalian central nervous system, present in over 80% of synapses. It is synthesized from glutamine via glutaminase in astrocytes and presynaptic neurons.

Glutamate Receptors

• Ionotropic Receptors:
• NMDA (N-methyl-D-aspartate) Receptor: A complex, voltage-gated and ligand-gated ion channel permeable to $Ca^{2+}$ and $Na^+$. At resting membrane potentials, the NMDA channel pore is physically blocked by an extracellular magnesium ion ($Mg^{2+}$). Channel activation requires both glutamate binding, glycine/D-serine co-agonist binding, and membrane depolarization (to expel $Mg^{2+}$). Excessive NMDA activation causes massive $Ca^{2+}$ influx, triggering excitotoxic neuronal death (implicated in stroke, ALS, and dementia).
• AMPA & Kainate Receptors: Fast-acting ligand-gated $Na^+$ channels mediating rapid excitatory neurotransmission.
• The NMDA Hypofunction Hypothesis of Schizophrenia: Non-competitive NMDA receptor antagonists like Phencyclidine (PCP) and Ketamine induce full-spectrum positive, negative, and cognitive symptoms of Schizophrenia in healthy individuals. NMDA hypofunction on GABA interneurons disinhibits downstream cortical glutamate pathways.
• Rapid Antidepressant Action of Ketamine/Esketamine: Sub-anesthetic IV ketamine or intranasal esketamine transiently blocks NMDA receptors on GABAergic interneurons, causing a rapid 'glutamate burst' that activates postsynaptic AMPA receptors. This stimulates downstream mTORC1 signaling and upregulates BDNF, driving rapid synaptogenesis within hours.

---

2. GABA ($\gamma$-Aminobutyric Acid - Major Inhibitory Neurotransmitter)

GABA is synthesized directly from glutamate by the enzyme Glutamic Acid Decarboxylase (GAD), using Vitamin B6 (pyridoxal phosphate) as an essential cofactor.

• $GABA_A$ Receptor: An ionotropic heteropentameric ligand-gated Chloride ($Cl^-$) channel. Binding of GABA opens the pore, causing $Cl^-$ influx, cellular hyperpolarization, and immediate membrane stabilization against excitation.
• Allosteric Modulation: Benzodiazepines bind to a specific allosteric site ($GABA_A ,\gamma_2$ subunit junction) to increase the frequency of channel opening in the presence of GABA. Barbiturates bind a distinct site to increase the duration of channel opening. Alcohol and non-benzodiazepine 'Z-drugs' (Zolpidem, Eszopiclone) also act as positive allosteric modulators at $GABA_A$ receptors.
• $GABA_B$ Receptor: A metabotropic GPCR coupled to $G_{\alpha i}$, opening inward-rectifying $K^+$ channels and inhibiting presynaptic $Ca^{2+}$ channels. Target of the muscle relaxant Baclofen and implicated in alcohol dependence (Acamprosate modulation).

---

Acetylcholine and Synaptic Dynamics

Acetylcholine (ACh)

Synthesized from acetyl-CoA and choline by choline acetyltransferase (ChAT) in forebrain cholinergic nuclei, particularly the Nucleus Basalis of Meynert.

• Nicotinic Receptors: Ionotropic ligand-gated cation channels ($Na^+/K^+$). High density in VTA; activation by nicotine drives mesolimbic dopamine release, accounting for high rates of tobacco dependence in psychiatric populations.
• Muscarinic Receptors ($M_1-M_5$): GPCRs distributed throughout the CNS and autonomic nervous system.
• Clinical Impact: Degeneration of cholinergic projections from the Nucleus Basalis of Meynert is the primary neurochemical pathology in Alzheimer's Disease, treated with Acetylcholinesterase Inhibitors (AChEIs: Donepezil, Rivastigmine, Galantamine). Central/peripheral muscarinic blockade by tricyclic antidepressants, low-potency typical antipsychotics (e.g., Chlorpromazine), and Clozapine induces severe anticholinergic toxicity (memory loss, confusion, delirium, hyperthermia, anhydrosis, urinary retention, constipation, tachycardia).

Inactivation and Transporters

Neurotransmitter action is terminated via two primary mechanisms:

1. Reuptake Transporters: High-affinity presynaptic monoamine transporters—DAT (dopamine), SERT (serotonin), NET (norepinephrine)—clear neurotransmitters from the synaptic cleft into presynaptic terminals. SSRIs, SNRIs, and NDRIs (Bupropion) exert clinical actions by inhibiting these specific reuptake pumps.
2. Enzymatic Degradation:

• Monoamine Oxidase (MAO): MAO-A preferentially metabolizes 5-HT, NE, and DA; MAO-B preferentially metabolizes DA and tyramine. MAO Inhibitors (Phenelzine, Tranylcypromine, Selegiline) prevent intraneuronal degradation of monoamines.
• Catechol-O-Methyltransferase (COMT): Degrades extracellular catecholamines (DA, NE), particularly critical in the Prefrontal Cortex where DAT expression is sparse.
• Vesicular Monoamine Transporter 2 (VMAT2): Packages cytoplasmic monoamines into presynaptic vesicles. VMAT2 Inhibitors (Valbenazine, Deutetrabenazine) deplete presynaptic dopamine stores, serving as first-line FDA-approved treatments for Tardive Dyskinesia.

---

Clinical Case Vignette

Vignette: A 28-year-old female with Schizophrenia stabilized on Olanzapine 15 mg daily presents with concerns regarding a 25-pound weight gain, hyperphagia, and sedation over the past 4 months. She denies tremors, muscle stiffness, or restlessness. Laboratory workup reveals elevated fasting blood glucose and dyslipidemia.

Clinical Analysis: Olanzapine's metabolic side-effect profile (weight gain, hyperphagia, metabolic syndrome) is directly mediated by potent antagonism at 5-HT2C serotonergic receptors and H1 histaminergic receptors. Its low propensity for EPS is attributed to concurrent 5-HT2A receptor blockade.